GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Stock Based Compensation

Akari Therapeutics (FRA:CLA) Stock Based Compensation : €0.53 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Stock Based Compensation?

Akari Therapeutics's Stock Based Compensation for the three months ended in Mar. 2024 was €0.28 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was €0.53 Mil.

Akari Therapeutics Stock Based Compensation Historical Data

The historical data trend for Akari Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Stock Based Compensation Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.95 0.27 0.27 0.70 1.06

Akari Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.25 0.26 - 0.28

Akari Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.53 Mil.

Akari Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics (FRA:CLA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Stock Based Compensation
Comparable Companies
IGC MYMD ENTX INDP PMCB AZTR EQ IGXT ONCT TCRT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
AKTX:USA
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Website
https://www.akaritx.com
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.